CA-ENEVATE
14.1.2020 12:02:06 CET | Business Wire | Press release
Enevate , a pioneer in advanced silicon-dominant lithium-ion (Li-ion) battery technology capable of extreme fast charging for electric vehicles (EVs), announced its new 4th generation technology optimized for high volume commercialization and manufacturing at gigafactory scale. Enevate is providing a solution to a difficult problem for automotive OEMs and EV battery manufacturers – providing extreme fast charging with high energy density and at lower material cost than conventional Li-ion batteries, while being compatible with existing battery fabrication facilities.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200114005035/en/
The new XFC-Energy™ technology achieves 5-minute charging to 75 percent capacity with 800 Wh/L cell energy density. Today’s conventional large-format Li-ion EV cells are at 500-600 Wh/L and typically take over 1 hour to charge.
“Mass EV adoption by consumers and fleet owners will depend to a large degree on advanced battery technology that will remove current barriers to entry such as long charging times and limited range,” said Christian Noske , Chairman of Alliance Ventures (Renault-Nissan-Mitsubishi). “Enevate is a key enabler for electric vehicles that are affordable, easy and quick to charge, and clean.”
Dr. John Goodenough , a recipient of the 2019 Nobel Prize in chemistry for groundbreaking work in the development of lithium-ion batteries and who has served on Enevate’s Advisory Board since 2010, added: “I salute the Enevate team for reaching this next important step in fulfilling the company’s mission to develop and commercialize innovative battery technologies to accelerate the adoption of electrified mobility.”
Enevate’s 4th generation XFC-Energy technology stands to be a game-changer for the EV industry, providing a path to produce extreme fast-charge EV batteries at low cost and high-volume production. Enevate is currently working with multiple automotive OEMs and EV battery manufacturers to commercialize its technology for 2024-2025 model year EVs, utilizing existing manufacturing infrastructure with minimal investment required, a core goal of its development.
Enevate’s 4th generation is the latest result of over 74 million hours of battery cell testing by Enevate’s scientists, 1 million meters of electrodes produced in the company’s R&D pilot line, and 2 billion test datapoints.
Enevate Founder and Chief Technology Officer Dr. Benjamin Park noted that Enevate’s XFC-Energy technology has been designed for large-format pouch, prismatic and cylindrical EV cells, utilizing its pure silicon anode paired with nickel-rich NCA, NCM and NCMA advanced cathodes.
“Enevate’s extreme fast charge technology enables a future where gas stations become drive-through EV charging stations – a win-win for consumers and the environment as electric vehicles replace those using gasoline,” Dr. Park said. “Enevate’s technology will help close the usability gap between today’s EVs and gas cars.”
Dr. Park will be discussing Enevate’s technology on January 15 at the Advanced Automotive Battery Conference in Weisbaden, Germany, in a presentation titled “Charging Ahead: Commercializing Fast-Charge Si-Dominant Li-ion Cells for EVs.”
XFC-Energy Technology Technical Details
- Cell technology scalable for large-format pouch, prismatic and cylindrical EV cells suitable for various battery module and pack architectures. Achieves 800 Wh/L and 340 Wh/kg in large-format EV cells.
- Pure silicon-dominant anode technology tunable with 10-60µm thickness and 1000-2000mAh/g that can be paired with NCA, NCM811, NCMA, low-cobalt, or other advanced cathode technologies.
- Continuous roll-to-roll anode manufacturing processes designed and capable of achieving over 80 meters per minute electrode production, over 10 GWh per electrode production line, with pure silicon anode rolls greater than 1 meter wide and longer than 5 kilometers in length sufficient for high volume gigafactory production, among other features.
- Lower anode material cost (dollar per kWh) than conventional and synthetic graphite.
- Transformative performance improvement, with five-minute charge to 75 percent of battery capacity, and, when paired with a high-nickel cathode, capable of over 1000 cycles using an EV drive cycle test and operation at -20˚C and below temperatures.
- Bottom line: Five-minute extreme fast charging, high energy density, low temperature operation, low cost and superior safety.
ABOUT ENEVATE (www.enevate.com)
Enevate develops and licenses advanced silicon-dominant Li-ion battery technology for electric vehicles (EVs), with a vision to charging EVs as fast as refueling gas cars and accelerating their mass adoption. With a portfolio of more than 200 patents issued and in process, Enevate’s pioneering advancements in silicon-dominant anodes and cells have resulted in battery technology that features five-minute extreme fast charging with high energy density, low temperature operation for cold climates, low cost and safety advantages over conventional Li-ion batteries.
Enevate’s vision is to develop and propagate EV battery technology that contributes to a clean and sustainable environment. The Irvine, California-based company has raised over $110 million from investors including Renault-Nissan-Mitsubishi (Alliance Ventures), LG Chem, Samsung, Mission Ventures, Draper Fisher Jurvetson, Tsing Capital, Infinite Potential Technologies, Presidio Ventures – a Sumitomo Corporation company, Lenovo, CEC Capital and Bangchak. Enevate®, the Enevate logo, XFC-Energy™, HD-Energy®, and eBoost® are registered trademarks of Enevate Corporation.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200114005035/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
